Ongoing operating losses
The company has a long history of losses and must keep investing in clinical studies, sales, and lab capacity before profitability is reached.
- Scope
- Cash burn and financing needs
- Materiality
- high
Guardant Health, Inc.
Guardant Health is a precision oncology company built around blood- and tissue-based cancer tests, real-world data, and AI analytics. Its products are used to help detect cancer earlier, monitor recurrence, and guide treatment selection, with a growing mix of clinical testing, biopharma services, and screening revenue.
−40,5 %
64,5 %
−42,4 %
+32,9 %
4.84
4.56
| % | |
|---|---|
| Oncology clinical testing | 55% Blood and tissue tests used by clinicians for therapy selection, monitoring, and recurrence detection. |
| Screening | 20% Shield screening tests sold for early cancer detection in average-risk populations. |
| Biopharma and data services | 20% Companion diagnostic development, regulatory support, monitoring, data services, and referral services for drug developers. |
| Licensing and other | 5% Technology licensing and other ancillary revenue streams tied to proprietary sequencing and analytics. |
Customers include oncologists, hospitals, cancer centers, research institutions, and patients who need actionable...
- Clinical oncology providersprimary
Hospitals, cancer centers, and physicians order Guardant tests to guide therapy selection and monitor disease.
- Biopharmaceutical companiesprimary
Drug developers buy companion diagnostic, monitoring, and data services to support trials and approvals.
- Screening patients and providerssecondary
Average-risk individuals and their clinicians use Shield for early cancer detection when coverage is available.
- Payers and government programsprimary
Medicare, Medicare Advantage, and VA coverage determine reimbursement and patient access for tests.
The business is centered in the United States, where reimbursement from Medicare, private payers, and the VA is...
- •United States is the core market for clinical and screening revenue
- •Medicare and VA coverage materially affect U.S. adoption and access
- •Japan is an important regulated market for Guardant360 CDx
- •Europe and Asia partnerships support international commercialization
- •Lab and partner network matters because tests depend on sample logistics
Guardant is expanding from advanced cancer testing into earlier-stage detection and broader multi-modal biology through...
01
Expand screening adoption for Shieldshort-term
Screening opens a much larger addressable market than advanced oncology testing and depends on reimbursement and physician adoption.
02
Broaden the oncology portfoliomedium-term
More tests across therapy selection and recurrence monitoring increase share of wallet across the cancer care continuum.
03
Scale biopharma and data servicesmedium-term
Biopharma relationships diversify revenue and monetize Guardant’s data, assays, and regulatory expertise.
04
Build new products from multi-modal biologylong-term
The Smart Platform and AI analytics are intended to create differentiated next-generation tests.
Guardant remains loss-making and depends on continued revenue growth, reimbursement expansion, and access to capital to...
Payer coverage and reimbursement risk
Revenue depends on Medicare, private payer, and government reimbursement decisions for clinical and screening tests.
- Scope
- Oncology and Shield screening revenue
- Materiality
- high
Supplier and lab operations disruption
The company relies on limited or sole suppliers, including Illumina for sequencers and maintenance.
- Scope
- Testing throughput and service continuity
- Materiality
- high
Biopharma customer concentration
A limited number of biopharma customers can materially affect revenue if programs end or are delayed.
- Scope
- Biopharma and data revenue
- Materiality
- high
Regulatory and approval risk
New tests and international commercialization depend on FDA and foreign regulatory approvals.
- Scope
- Product launches and Japan/other markets
- Materiality
- medium
Revenue recognition and variable consideration
Affects top-line growth and gross margin comparability
Stock-based compensation
Can materially affect operating loss and non-cash expense
Receivables and inventory estimates
Affects cash conversion and balance sheet quality
Cash burn and financing capacity
Influences dilution and capital structure
Guardian Pharmacy Services, Inc.
GRDN · Retail-Drug Stores and Proprietary Stores
Concentra Group Holdings Parent, Inc.
CON · Services-Specialty Outpatient Facilities, NEC
InspireMD, Inc.
NSPR · Surgical & Medical Instruments & Apparatus
Alignment Healthcare, Inc.
ALHC · Hospital & Medical Service Plans
Elevance Health, Inc.
ELV · Hospital & Medical Service Plans
Elevance Health is a U.S.
HEALTHCARE SERVICES GROUP INC
HCSG · Services-Nursing & Personal Care Facilities
: 28.4.2026